Clinical trials · New York, NY
Metastatic Prostate Cancer clinical trials in New York
We’re tracking 141 recruiting metastatic prostate cancer studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06072612RecruitingPhase 3
Bria-IMT plus CPI vs standard care for advanced breast cancer
This trial tests a new combination of two immunotherapy drugs (Bria-IMT and a checkpoint inhibitor) against your doctor's choice of standard treatments. It is for people with advanced breast cancer that has spread and who have already tried several prior therapies.
New York, New YorkAges 18 years+ - NCT06067841RecruitingPhase 1
New drug for advanced prostate cancer
This study tests a new drug (BMS-986460) for people with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can shrink or slow the cancer.
New York, New YorkAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
New York, New YorkAges 18 years+ - NCT06844383RecruitingPhase 2
Talazoparib with or without enzalutamide for prostate cancer after prior treatment
This study tests a drug called talazoparib, either alone or combined with enzalutamide, in people with prostate cancer that has spread and has a specific genetic change. The goal is to see if this treatment can help control the cancer after previous therapies have stopped working.
New York, New YorkAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
New York, New YorkAges 18 years+ - NCT05915442RecruitingPhase 2
Adenosine blocker plus immunotherapy for limited prostate spread
This Phase 2 study tests a medicine that affects “adenosine” signaling along with an immune checkpoint inhibitor (immunotherapy) in men with hormone-sensitive prostate cancer that has spread in only a small, limited way. It aims to stop or slow that limited spread by helping the immune system work better.
New York, New YorkAges 18–99 - NCT06855277RecruitingPhase 3
AAA817 with hormone therapy for advanced prostate cancer
This trial tests a new combination treatment (AAA817 plus a hormone therapy) against standard care for men with advanced PSMA-positive prostate cancer that has spread and stopped responding to a previous hormone therapy. It may be an option if you haven't had certain prior treatments.
New York, New YorkAges 18–100 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New York, New YorkAges 18 years+ - NCT07590934RecruitingPhase 1/Phase 2
Drug combination study for advanced prostate cancer
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
New York, New YorkAges 18–99 - NCT07277322RecruitingPhase 1/Phase 2
Two immunotherapy drugs before surgery for MSS colorectal cancer with liver spots
This trial tests a combination of two immunotherapy drugs (Dupilumab and Toripalimab) before surgery for people with MSS colorectal cancer that has spread to the liver. The goal is to see if this treatment can shrink the liver tumors and help the body's immune system fight the cancer.
New York, New YorkAges 18 years+ - NCT03492424Recruiting
Focal prostate cancer treatment study
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
New York, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
New York, New YorkAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
New York, New YorkAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
New York, New YorkAges 18 years+ - NCT07203482Recruiting
HIFU ablation treatment for prostate cancer outcomes
This study collects data on men with early, low-risk prostate cancer who choose to have a targeted ultrasound treatment called HIFU (High-Intensity Focused Ultrasound). It looks at how well this treatment works and how men recover.
New York, New YorkAges 40–95 - NCT04886986RecruitingPhase 1
Testing a targeted radiation pill for advanced prostate cancer
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
New York, New YorkAges 18–99 - NCT07319871RecruitingPhase 1
Study of two drugs for prostate cancer
This trial tests a new combination of two drugs, pasritamig and JNJ-86974680, for men with a certain type of advanced prostate cancer that has spread to bone or lymph nodes but not to organs like the lungs or liver. It aims to see if this combination is safe and effective.
New York, New YorkAges 18 years+ - NCT07082920RecruitingPhase 1
Combination treatment for advanced prostate cancer
This study tests a combination of two new investigational drugs for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drugs aim to help your immune system fight the cancer cells.
New York, New YorkAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT04946370RecruitingPhase 1/Phase 2
Pembrolizumab plus prostate cancer drug, with or without radiation
This early-phase trial tests pembrolizumab (an immune therapy) plus an androgen-receptor–blocking prostate cancer drug, and possibly a targeted radiation treatment. It’s for men with prostate cancer that has spread and keeps worsening despite standard hormone therapy, aiming to shrink tumors and improve control of the disease.
New York, New YorkAges 18 years+ - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
New York, New YorkAges 18 years+ - NCT04423211RecruitingPhase 3
Surgery-recovered prostate cancer treated with PET-guided radiation
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
New York, New YorkAges 18 years+ - NCT07184957Recruiting
Cryotherapy for localized prostate cancer: a data study
This study tracks outcomes for men who choose cryotherapy (freezing cancer cells) to treat prostate cancer that hasn't spread. It helps doctors understand how well this treatment works.
New York, New YorkAges 40–85 - NCT06141993Recruiting
Study of blood markers in hormone therapy resistance for prostate cancer
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
New York, New YorkAges 18 years+
Hear when a new Metastatic Prostate Cancer trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Metastatic Prostate Cancer trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting metastatic prostate cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 4 studies
- Columbia University Irving Medical Center · 3 studies
- Research Site · 3 studies
- Stony Brook University Medical Center · 3 studies
- Community Medical Center · 2 studies
- Hackensack University Medical Center · 2 studies
- Icahn School of Medicine at Mount Sinai / Mount Sinai Hospital · 2 studies
- Lenox Hill Hospital · 2 studies
What taking part in a metastatic prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic prostate cancer studies in New York.
Common questions
- Are there metastatic prostate cancer clinical trials near New York?
- Yes. We're currently tracking 141 recruiting metastatic prostate cancer studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate cancer study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate cancer studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.